



HAL
open science

A scoping review identifies multiple comments suggesting modifications to SPIRIT 2013 and CONSORT 2010

Camilla H Nejstgaard, Isabelle Boutron, An-Wen Chan, Ryan Chow, Sally Hopewell, Mouayad Masalkhi, David Moher, Kenneth F Schulz, Nathan A Shlobin, Lasse Østengaard, et al.

► To cite this version:

Camilla H Nejstgaard, Isabelle Boutron, An-Wen Chan, Ryan Chow, Sally Hopewell, et al.. A scoping review identifies multiple comments suggesting modifications to SPIRIT 2013 and CONSORT 2010. *Journal of Clinical Epidemiology*, 2023, 155, pp.48-63. 10.1016/j.jclinepi.2023.01.003 . hal-04086343

HAL Id: hal-04086343

<https://cnam.hal.science/hal-04086343>

Submitted on 2 May 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

REVIEW ARTICLE

A scoping review identifies multiple comments suggesting modifications to SPIRIT 2013 and CONSORT 2010

Camilla H. Nejtgaard^{a,b,*}, Isabelle Boutron^{c,d}, An-Wen Chan^e, Ryan Chow^f, Sally Hopewell^g,
Mouayad Masalkhi^h, David Moher^{i,j}, Kenneth F. Schulz^k, Nathan A. Shlobin^l,
Lasse Østengaard^{a,b,m}, Asbjørn Hróbjartsson^{a,b}

^aCentre for Evidence-Based Medicine Odense (CEBMO) and Cochrane Denmark, Department of Clinical Research, University of Southern Denmark, Denmark

^bOpen Patient Data Explorative Network (OPEN), Odense University Hospital, Denmark

^cUniversité Paris Cité, Centre de Recherche in Epidemiology and Statistics (CRESS), Inserm, France

^dCochrane France, France

^eDepartment of Medicine, Women's College Research Institute, University of Toronto, Canada

^fFaculty of Medicine, University of Ottawa, Canada

^gOxford Clinical Trials Research Unit/Centre for Statistics in Medicine, University of Oxford, Oxford, UK

^hSchool of Medicine, University College Dublin, Ireland

ⁱCentre for Journalology, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Canada

^jSchool of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Canada

^kDepartment of Obstetrics and Gynecology, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

^lDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

^mUniversity Library of Southern Denmark, University of Southern Denmark, Odense, Denmark

Accepted 12 January 2023; Published online 18 January 2023

Abstract

Objectives: To identify, summarize, and analyse comments on the core reporting guidelines for protocols of randomized trials (Standard Protocol Items: Recommendations for Interventional Trials [SPIRIT] 2013) and for completed trials (Consolidated Standards of Reporting Trials [CONSORT] 2010), with special emphasis on suggestions for guideline modifications.

Methods: We included documents written in English and published after 2010 that explicitly commented on SPIRIT 2013 or CONSORT 2010. We searched four bibliographic databases (Embase and MEDLINE to June 2022; Web of Science and Google Scholar to April 2022) and other sources (e.g., the EQUATOR Network website, the BMC Blog Network, and the BMJ rapid response section). Two authors independently assessed documents for eligibility and extracted data on basic characteristics and the wording of the main comments. We categorized comments as 'suggestion for modification to the wording of an existing guideline item,' 'suggestion for a new item,' or 'reflections on challenges or strengths.' We provided a summary and examples of the proposed suggestions and categorized comments into those that were directly linked to empirical investigations, were continuations of previous methodological discussions, or reflected new methodological developments.

Results: We assessed full text of 2,320 potentially eligible documents and included 93 documents with 114 comments. In total, 37 comments suggested modifications to existing guideline items. The participant flow section of CONSORT 2010 received the most comments (eight comments made different suggestions, e.g., one comment suggested to add numbers on nonrandomized screened participants). There were 46 comments suggesting new items. Multiple suggestions were related to trial interventions (eight comments made different suggestions, e.g., one comment suggested to add content on cointerventions), blinding (six comments suggested to add content on risk

Funding source: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data statement: The dataset used and analysed during this study is available upon request.

Declarations of interest: I.B., A-W. C., S.H., D.M., K.F.S., and A.H. are part of the joint executive group for the planned updates of SPIRIT and CONSORT. D.M. and A.H. are members of the editorial board of the Journal of Clinical Epidemiology.

Conflict of Interest: The authors declare no additional conflicts of interest.

Author Contributions: The review protocol was developed by C.H.N., I.B., A-W. C., S.H., D.M., K.F.S., L.Ø., and A.H. C.H.N., R.C., M.M., N.A.S., L.Ø., and A.H. assessed documents for inclusion and/or extracted data. C.H.N. performed the data analysis, and all authors participated in data interpretation. C.H.N. and A.H. wrote the draft review and all authors contributed in revising the review.

* Corresponding author. Centre for Evidence-Based Medicine Odense (CEBMO) & Cochrane Denmark, University of Southern Denmark, J.B. Winsløvs Vej 9b, 3rd Floor, 5000 Odense, Denmark. Tel.: +45-23-60-44-74. E-mail address: cahansen@health.sdu.dk (C.H. Nejtgaard).

of unblinding), statistical methods (five comments made different suggestions, e.g., one comment suggested to add content on blinding of statisticians), and participant flow (seven comments made different suggestions, e.g., three comments suggested to add content on missing data). Half (53%) of the suggestions were directly linked to empirical investigations. Six (7%) suggestions were continuations of previous methodological discussions and five (6%) suggestions reflected new methodological developments related to conflicts of interest and funding, data sharing, and patient and public involvement.

Conclusion: The issues raised provide context to authors, peer reviewers, editors, and readers of trials using SPIRIT 2013 and CONSORT 2010 and inform the planned updates of the core guidelines. © 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Keywords: SPIRIT; CONSORT; Reporting guidelines; Clinical trials; Comment; Reporting

1. Introduction

Results from randomized trials have a profound impact on patient care. When appropriately designed, conducted, and reported they provide trustworthy measurements of the effect of healthcare interventions. Reporting the rationale and core methods in a protocol is a key part of conducting a randomized trial. A protocol enables appropriate assessment of the trial before it begins and full appraisal of the conduct and results after completion [1]. The importance of protocols is increasingly being recognized and some journals, such as BMJ, require authors of completed randomized trial reports to submit their study protocol alongside the report of the completed trial [2]. For completed trials, a similarly important step is the adequate reporting of protocol changes, results, interpretations, and conclusions, typically in a trial report. Adequate reporting of a trial enables appraisal of risk of bias, the appropriate applicability of its results, and inclusion of data in a meta-analysis.

Comprehensive, clear, and transparent reporting is a prerequisite for trial findings to reliably inform patient care and patient decision-making [3]. Unfortunately, important aspects are often not reported adequately [4]. Studies have shown that reporting of trial outcomes [5], blinding [6], sample size calculations [7], and allocation concealment [8] is often incomplete in trial protocols and completed reports.

To facilitate full reporting of information in trial protocols, the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guideline was developed in 2013 [1]. Similarly, to facilitate full reporting of completed trial reports, the Consolidated Standards of Reporting Trials (CONSORT) was developed in 1996 with subsequent updates in 2001 and 2010. The purpose of updating CONSORT was to prevent misinterpretation of specific items and to take into account new methodological developments [3].

SPIRIT 2013 and CONSORT 2010 are endorsed by many journals, regulators, research funders, editorial groups (e.g., the International Committee of Medical Journal Editors), and patient groups [9,10] and are used routinely by trial authors. Several years have passed since the release of the guidelines, and the context of clinical trial

methodology is continually evolving. Similarly, open science practices related to clinical trials (e.g., data management plans) have started to be mandated and/or recommended. Therefore, the executive group for SPIRIT and CONSORT is planning to jointly update both reporting guidelines [11].

Several researchers have commented on the usability of SPIRIT 2013 and CONSORT 2010. For example, Laursen et al. suggested to include recommendations to report run-in periods [12], and duVaure et al. commented on the lack of recommendations to report authors' financial conflicts of interest (and not only funding source) [13]. We thought it relevant to provide an overview of such comments.

The objective of this scoping review was to identify, summarize, and analyse comments on SPIRIT 2013 and CONSORT 2010, with special emphasis on suggestions for guideline modifications.

2. Methods

2.1. Terminology

We use the term 'documents' to refer to published texts that include comments on SPIRIT 2013 or CONSORT 2010. This may cover, for example, empirical studies, editorials, and blogs.

We use the term 'comments' to refer to explicit statements on SPIRIT 2013 or CONSORT 2010 expressed in the included documents.

2.2. Protocol and registration

This scoping review was based on a predefined protocol (available from OSF [14]). We reported the review in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews reporting guideline [15].

2.3. Eligibility criteria

We included documents written in English and published after 2010 that explicitly commented on either

What is new?

Key findings

- We identified 114 published comments on SPIRIT 2013 and CONSORT 2010. Comments commonly proposed modifications to the wording of the participant flow section of CONSORT 2010 ($N = 8$) and proposed new content related to the intervention ($N = 8$), blinding ($N = 6$), statistical methods ($N = 5$), and participant flow ($N = 7$) sections of both SPIRIT 2013 and CONSORT 2010.
- Half (53%) of the suggestions were directly linked to empirical investigations, whereas others were continuations of previous methodological discussions (7%) or reflected new methodological developments (6%).

What this adds to what is known?

- We used multiple approaches to identify documents. Our review precedes the planned update of the reporting guidelines. Many of the identified comments suggested adding new content to SPIRIT 2013 or CONSORT 2010 and none suggested deleting items. SPIRIT 2013 and CONSORT 2010 aim to address the minimum content relevant for all randomized trial protocols and reports. The forthcoming revision of the guidelines needs to prioritize which new items are the most important and which changes can be implemented without introducing unnecessary complexity.

What is the implication and what should change now?

- The issues raised may provide context to authors, peer reviewers, editors, and readers of trials using SPIRIT 2013 and CONSORT 2010 and inform the planned updates of the guidelines.

SPIRIT 2013 or CONSORT 2010. To be included, the documents had to mention SPIRIT 2013 or CONSORT 2010 somewhere in the text (i.e., not necessarily in the title or abstract). We only included comments on the most recent version of CONSORT (either stated directly by the document authors or verified by us based on the reference lists). We included opinion pieces (e.g., commentaries, letters, and editorials) and empirical studies and literature reviews. We also included suggestions for modifications and comments sent to members of the steering group of SPIRIT or CONSORT or posted on key websites (e.g., the EQUATOR Network website, <https://www.equator-network.org/>).

To be included, documents had to suggest modifications to SPIRIT 2013 or CONSORT 2010 or reflect on their challenges or strengths. Documents commenting on other aspects of the reporting guidelines (e.g., explaining the basis of the guidelines) were excluded. Thus, we excluded empirical studies that investigated the use of the guidelines but did not suggest modifications. We excluded documents that had only generic comments (e.g., briefly mentioning that CONSORT 2010 is a resource) or had only comments on implementation or endorsement of SPIRIT 2013 or CONSORT 2010. We excluded ‘peripheral remarks’ on the reporting guidelines (defined as very short remarks, i.e., no more than one sentence). We also excluded documents that had only comments related to SPIRIT or CONSORT extensions unless the suggestions were also relevant for the main guidelines. Finally, we excluded documents with comments suggesting the development of new extensions (e.g., suggestion to develop reporting recommendations for surgical adverse events [16]) and comments addressing application of SPIRIT 2013 or CONSORT 2010 on a specific subgroup of trials (e.g., suggestion to modify CONSORT 2010 to therapeutic medical devices [17]).

2.4. Information sources and search for documents

In a previous study investigating comments on the Cochrane tool for assessing risk of bias in randomized trials, it proved challenging to strike an appropriate balance between search sensitivity and specificity [18]. Therefore, we used multiple approaches to identify documents. The search strategy was developed in liaison with a search specialist (L.Ø.).

First, we performed a systematic basic search in two databases: Embase and MEDLINE (from January 2010 to June 2022). We used the search strategies in [Appendix 1](#). We reviewed the search strategy using the PRESS 2015 Evidence-Based Checklist [19] in collaboration with a search specialist.

Second, we performed a focused search among documents citing SPIRIT 2013 or CONSORT 2010. We used Web of Science (from January 2010 to April 2022) to identify studies citing any of the SPIRIT 2013 or CONSORT 2010 statement or explanation publications listed on the SPIRIT or CONSORT websites where a Digital Object Identifier was available. We used the refine search function and the search terms in [Appendix 2](#) to identify potentially eligible documents.

Third, we used Google Scholar (from January 2010 to April 2022) to conduct full text searches. We used standard phrases from the statement and explanation publications of the reporting guidelines and comments identified through the database searches ([Appendix 3](#)). For each search, we sorted the search records by relevance and stopped screening when no additional documents had been identified for a substantial amount of the sorted documents (> 50 records).

Fourth, we searched key websites (e.g., the EQUATOR Network website [20]), blogs (e.g., the BMC Blog Network [21]), and responses or comments to the SPIRIT 2013 or CONSORT 2010 statement or elaboration papers (e.g., through the BMJ rapid response section [22]) for additional documents (from January 2010 to April 2022). We searched proceedings from Cochrane Colloquia (covering conferences from 2010 to the most recent in 2020) [23] for conference abstracts with SPIRIT or CONSORT in the title and/or abstract.

Finally, we read reference lists of key publications and inspected personal files of the authors of this review and the executive group for SPIRIT and CONSORT.

2.5. Selection of documents for inclusion

From the searches in Embase and MEDLINE, duplicates were removed using EndNote and search records were managed using Covidence. One author (primarily C.H.N. or L.Ø.) screened titles and abstracts of all search records for obvious exclusion. One author (C.H.N. or N.A.S.) electronically screened full texts to exclude records with no mentioning of SPIRIT 2013 or CONSORT 2010, with sole mentioning of SPIRIT or CONSORT extensions, or not written in English. Two authors (C.H.N. and either R.C., M.M., or L.Ø.) independently screened remaining full texts of potentially eligible documents.

One author (C.H.N.) performed the additional searches. All eligible documents identified through these searches were verified for inclusion by a second author (R.C. or M.M.).

2.6. Data extraction

Two authors (C.H.N. and either R.C. or M.M.) independently extracted data and coded comments from each included document. Data were extracted into a pilot tested Excel sheet. We extracted the following basic characteristics of each document: first author, publication year, publication type (e.g., editorial or empirical study), and reporting guideline considered (i.e., SPIRIT 2013, CONSORT 2010, or both). We also extracted the exact wording of the main comments from each included document. One document could contain several comments. We defined separate comments as comments related to separate items or sections of the reporting guidelines.

We categorized comments as ‘suggestion for modification to the wording of an existing guideline item,’ ‘suggestion for a new item,’ or ‘reflections on challenges or strengths.’ We noted the SPIRIT 2013/CONSORT 2010 topic the comment was addressing (e.g., methods or results), and, when relevant, the specific SPIRIT 2013/CONSORT 2010 item number. For comments categorized as ‘suggestion for modification to the wording of an existing guideline item’ and ‘suggestion for a new item’, one author (C.H.N.) phrased a key point and this was verified by two

authors (R.C. and M.M.) independently. Moreover, one author (C.H.N.) categorized the importance of such comments (e.g., suggestion directly linked to an empirical investigation) and this was verified by a second author (A.H.).

2.7. Synthesis of results

We noted the numerical distribution of included documents and comments within each category and theme. We categorized each comment into SPIRIT 2013/CONSORT 2010 themes to merge similar topics. We qualitatively mapped the themes addressed by the documents. For comments categorized as ‘suggestion for modification to the wording of an existing guideline item’ or ‘suggestion for a new item’, we provided a summary and examples of the proposed suggestions.

We furthermore categorized comments into those that were directly linked to an empirical investigation, were continuations of previous methodological discussions, or reflected new methodological developments.


For comments categorized as ‘reflections on challenges or strengths’, we listed relevant comments in a table and provided a brief overview.

3. Results

We electronically or manually assessed full text of 2,320 potentially eligible documents (1,366 identified through MEDLINE and Embase, 954 identified through other sources) and included 93 published documents with 114 comments (Fig. 1 and Appendix 4). The documents were either empirical studies (69%) or opinion pieces (31%). Most of the 93 documents (87%) had comments that were primarily intended for CONSORT 2010 (Table 1). The majority of the 114 comments were related to the methods section (48 comments, 42%) or results section (31 comments, 27%) of the reporting guidelines.

3.1. Suggestions for modifications to the wording of existing guideline items

In total, 37 comments were suggestions for modifications of existing guideline items. The comments covered all main sections of the reporting guidelines but were mostly related to the methods (14 comments) and results (12 comments) sections. The topic receiving the most comments was the participant flow section of CONSORT 2010 (item 13a and 13b). In eight comments, the authors suggested modifications to the enrolment (e.g., add numbers on nonrandomized screened participants), allocation (e.g., clarify reasons for exclusion following randomisation), follow-up (e.g., add duration of follow-up), analysis (e.g., add number of participants with and without the measured outcome), and design (e.g., remove connecting line between follow-up section and analysis section) parts of the



*Number of records identified in the databases; †Number of full text records identified through other sources. These searches were performed by one author, and we did not record exclusion reasons. All eligible documents were verified for inclusion by a second author.

Fig. 1. Flow chart of the inclusion of documents.

CONSORT 2010 flow diagram (Table 2 and Appendix 5). Furthermore, multiple comments were related to the intervention (three comments made different suggestions, e.g., two comments suggested to include details on timing of the treatments), statistical methods (three comments made different suggestions, e.g., one comment suggested to include detailed guidance on the use and reporting of subgroup analyses), the harms results (three comments made different suggestions, e.g., one comment suggested to require all harms to be reported rather than just important harms), and interpretation of findings (four comments made different suggestions, e.g., one comment suggested to include a statement on blinded interpretation) parts of SPIRIT 2013 and CONSORT 2010 (Table 2 and Appendix 5).

3.2. Suggestions for new items

In 46 comments, suggestions for new items were made. The comments were mostly related to the methods section (21 comments). The intervention section of SPIRIT 2013 and CONSORT 2010 received the most comments. In eight comments, the authors made different suggestions. For example, comments suggested to add content on quality of the drugs used, intervention implementation strategies, and cointerventions (Table 3 and Appendix 6). Furthermore, multiple comments were related to the blinding (six comments suggested to add content on risk of unblinding), statistical methods (five comments made different suggestions, e.g., one comment suggested to add content on blinding of statisticians), and participant flow (seven comments made

Table 1. Characteristics of documents commenting on SPIRIT 2013 or CONSORT 2010

Document characteristics	N (%) of included documents
Publication type	
Empirical study ^a	64 (69)
Opinion piece ^b	29 (31)
Document publication year	
2010–2012	25 (27)
2013–2015	20 (22)
2016–2018	19 (20)
2019–2022	29 (31)
Reporting guideline considered	
SPIRIT 2013	3 (3)
CONSORT 2010	81 (87)
Both SPIRIT 2013 and CONSORT 2010	9 (10)
Number of comments per document ^c	
1	84 (90)
2	4 (4)
3	3 (3)
5	1 (1)
8	1 (1)

^a Empirical studies include, for example, systematic reviews, experimental studies, and cross-sectional studies.

^b Opinion pieces include, for example, commentaries and letters.

^c Number of comments in each published document (one document may contain multiple comments on SPIRIT 2013 or CONSORT 2010).

different suggestions, e.g., three comments suggested to add content on missing data), and parts of SPIRIT 2013 and CONSORT 2010 (Table 3 and Appendix 6).

3.3. Importance of the proposed suggestions

Half (53%) of the suggestions for modifications of existing guideline items (37 comments) and new items (46 comments) were directly linked to empirical investigations. In most cases, the authors conducted an empirical study investigating reporting in a sample of randomized trials and proposed changes to SPIRIT 2013 and/or CONSORT 2010 on the basis of their findings. For example, Sweetman et al. investigated reporting in 80 trials and found that protocol violations were often under-reported. Therefore, they suggested to modify existing items on protocol amendments and provide explicit reporting requirements on protocol violations [24]. Moreover, Zhang et al. investigated reporting in 221 trials and found that reporting of subgroup analyses was neither uniform nor complete. Therefore, they suggested to modify existing items on statistical methods and include more detailed guidance on the use and reporting of subgroup analyses [25].

A few of the suggestions for modifications of existing guideline items (37 comments) and new items (46 comments) were continuations of previous methodological

discussions. In six comments (7%), the authors reacted on the removal of risk of unblinding from the CONSORT 2001 version [26]. Finally, five comments (6%) made suggestions that reflected new methodological developments. Two comments suggested to include reporting requirements related to trial authors' financial conflicts of interest and funding amount [13,27], two comments suggested to include reporting requirements of data sharing [28,29], and one comment suggested to include reporting requirements on patient and public involvement [30].

3.4. Reflections on challenges and strengths

In total, 28 comments reflected on challenges of SPIRIT 2013 and CONSORT 2010 and most of these were either related to the methods section (12 comments), results section (six comments), or were generic comments not related to any specific section (nine comments). In addition, three comments reflected on strengths of CONSORT 2010 (Table 4).

4. Discussion

4.1. Summary of main findings

Comments on SPIRIT 2013 and CONSORT 2010 made multiple suggestions for modifying the wording of existing guideline items and adding new items. The comments covered all aspects of the reporting guidelines but were often related to the methods or results section. Several comments proposed modifications to the wording of the participant flow section of CONSORT 2010 and several comments proposed adding content related to the intervention, blinding, statistical methods, and participant flow sections of SPIRIT 2013 and CONSORT 2010. Half of the suggestions were directly linked to empirical investigations and additional few comments were continuations of previous methodological discussions or reflected new methodological developments.

4.2. Strengths and weaknesses

We used multiple approaches to identify documents. Our review precedes the planned update of the reporting guidelines. However, it is challenging to search for documents with comments as not all are indexed in standard databases. We may not have identified all eligible documents but it is unlikely that any missing comments would change our main findings or qualitative conclusions.

4.3. Other similar studies

Our review complements previous studies that have focused on adherence and endorsement of the reporting guidelines. Empirical studies have reported that adherence to the CONSORT 2010 reporting guideline is suboptimal in, for example, addiction trials [31], COVID-19 trials [32], and in trials on statins or fibrates for diabetic

Table 2. Suggestions for modifications to the wording of existing guideline items (37 comments in 29 documents)

SPIRIT or CONSORT section and topic	Item number	Document ID	Comment primarily intended for	Key point
Title and abstract, comment related to title	SPIRIT 1 CONSORT 1a	Nicholls 2022	CONSORT	Include a statement on whether the trial report is primary or nonprimary (e.g., a subgroup analysis)
Other information, comment related to registration	SPIRIT 2a CONSORT 23	Reveiz 2010a	CONSORT	Include the timing of registration (prospectively or retrospectively registered trial)
Other information, comment related to funding	SPIRIT 4 CONSORT 25	Siddiq 2019	CONSORT	Include the funding amount or budget allocation, rewards, and reimbursements
Introduction, comment related to background and objectives	SPIRIT 7 CONSORT 2b	Nicholls 2022	CONSORT	Include details on the primary or nonprimary nature of the trial report (i.e., whether results are addressing primary objectives or secondary objectives only)
Methods: Participants, interventions, and outcomes, comment related to participants or study setting	SPIRIT 9 CONSORT 4b	Patterson 2010	CONSORT	Include an estimate of the potential study population (as an addition to ‘assessed for eligibility’) and details on planned and actual recruitment sites and strategies
Methods: Participants, interventions, and outcomes, comments related to participants or eligibility criteria	SPIRIT 10 CONSORT 4a	Cals 2011 Yelland 2019	CONSORT SPIRIT and CONSORT	Include details on the similarity between participants in the current trial and participants in previous trials that established efficacy of the control intervention Include information on repeat participation
Methods: Participants, interventions, and outcomes, comments related to interventions	SPIRIT 11a CONSORT 5	Bryant 2014 Cals 2011 Hoffmann 2014	CONSORT CONSORT CONSORT	Add details on the interventions, including: level (individual, cluster, or both), timing of treatment, content of intervention materials, administration and delivery (who and where), intervals between delivery of intervention components, any tailoring or standardization of the intervention, rationale for the type of control, and information on whether the control is identical to that in any previous trials that established efficacy
Methods: Participants, interventions, and outcomes, comment related to outcomes	SPIRIT 12 CONSORT 6b	Downey 2016	CONSORT	Include guidance on assessing composite outcome measures and the justifiable basis for changing outcome measurements
Methods: Participants, interventions, and outcomes, comments related to sample size	SPIRIT 14 CONSORT 7a	Cals 2011 Zakeri 2018	CONSORT CONSORT	Include details on whether and how clustering by care providers or centres was addressed ^a Include rationale for the hypothesized effect size (ideally based on evidence from prior research)
Methods: Assignment of interventions, comments related to blinding	SPIRIT 17a CONSORT 11a	Blanco 2018 Funada 2022	CONSORT CONSORT	Delete the phrase ‘if done’ Modify blinding items to separate and report each blinding
Methods: Data collection, management, and analysis, comments related to statistical methods	SPIRIT 20a CONSORT 12a SPIRIT 20b CONSORT 12b	Cals 2011 Rivoirard 2016 Zhang 2015	CONSORT CONSORT CONSORT	Include specification on whether a one-sided or two-sided confidence interval approach was used Include advice on checking if the tests used in the results section were consistent with those described in the methods section Include more detailed guidance on the use and reporting of subgroup analyses
Ethics and dissemination, comment related to protocol amendments	SPIRIT 25 CONSORT 3b	Sweetman 2011	CONSORT	Include explicit reporting requirements on protocol violations

(Continued)

Table 2. Continued

SPIRIT or CONSORT section and topic	Item number	Document ID	Comment primarily intended for	Key point
Ethics and dissemination, comment related to protocol	SPRIT 31c CONSORT 24	Revez 2010b	CONSORT	Include statement that protocols can be submitted in languages other than the language of the journal
Results, comments related to participant flow	CONSORT 13a, 13b and flow diagram	Cals 2011 Campbell 2016 Deo 2011 Hopewell 2011 Kearney 2017 Péron 2013 Rønsbo 2021 Wilson 2018	CONSORT CONSORT CONSORT CONSORT CONSORT CONSORT CONSORT	<p>Suggested modifications for existing parts:</p> <p>Enrollment:</p> <ul style="list-style-type: none"> - Number of participants or units approached to take part in the trial, the number which were eligible, and reasons for nonparticipation - More details on the process of inclusion - Numbers on nonrandomized screened participants - Details on participants in screening, eligibility, approached, and randomized stages <p>Allocation:</p> <ul style="list-style-type: none"> - Number of care providers or centres performing the intervention in each group - Number of patients treated by each care provider or in each centre - Add reasons for exclusion following randomisation <p>Follow-up:</p> <ul style="list-style-type: none"> - Time spent on the trial for all participants - Number of participants with unknown primary end point status and/or unknown vital status - Number of participants who discontinue study intervention - Duration of follow-up - More guidance on the difference between loss to follow-up and discontinuation of the intervention <p>Analysis:</p> <ul style="list-style-type: none"> - Number of participants with and without a measured outcome - Number of participants included or excluded in analysis - Categories to allow distinction between number analysed and number for whom the outcomes were known and imputed <p>Suggested modifications for the design:</p> <ul style="list-style-type: none"> - Remove connecting line between follow-up section and analysis section
Results, comment related to baseline data	CONSORT 15	Cals 2011	CONSORT	Include baseline data for each group at individual and cluster levels
Results, comments related to harms	CONSORT 19	Gorrell 2016 Jull 2020 Ting 2010	CONSORT CONSORT CONSORT	<p>Avoid the term ‘side effect’, prefer the term ‘adverse event’</p> <p>Require all harms to be reported rather than ‘important harms’</p> <p>Place emphasis on patient’s own first hand impression of adverse symptoms during trial participation and follow-up (rather than clinician impression)</p>

(Continued)

Table 2. Continued

SPRIT or CONSORT section and topic	Item number	Document ID	Comment primarily intended for	Key point
Discussion, comment related to limitations	CONSORT 20	Cals 2011	CONSORT	Include reflections on the choice of comparator, lack of or partial blinding, and unequal expertise of or recruitment by care providers or centres
Discussion, comments related to interpretation	CONSORT 22	Bacchetti 2010	CONSORT	Include guidance on how misinterpretation should be avoided (e.g., by clarifying that interpretation should take into account the estimated effects and its confidence interval rather than focusing on the <i>P</i> value)
		Jellison 2019	CONSORT	Include language discouraging spin
		Järvinen 2014	CONSORT	Include an explicit statement about whether the authors conducted blinded interpretation
		Nicholls 2022	CONSORT	Include a statement on the primary or nonprimary nature of the trial report

^a Comment also applicable to SPIRIT 2013 item 20a and CONSORT 2010 item 12a.

retinopathy [33]. Moreover, studies have reported that journal endorsement of previous versions of CONSORT and its extensions may improve reporting quality [34,35] and that the use of a CONSORT-based peer review tool (COBPeer) may improve peer reviewers ability to detect inadequate reporting in randomized trials [36].

The methods used in our scoping review are similar to those used in evaluations of other methodological tools. Jørgensen et al. summarized published comments on the first version of the Cochrane tool for assessing risk of bias in randomized clinical trials to provide a basis for a revision of the tool. They identified 68 comments that were categorized as per whether they expressed strengths, challenges, or suggestions to changes of the tool [18].

4.4. Mechanisms and perspectives

Many of the 114 comments suggested adding new content to SPIRIT 2013 or CONSORT 2010 and none suggested to delete items. SPIRIT 2013 and CONSORT 2010 aim to address the minimum content relevant for all randomized trial protocols and reports. The forthcoming revision of the guidelines needs to prioritize which new items are the most important and which changes can be implemented without introducing unnecessary complexity.

New methodological developments have emerged or received increasing attention since the development of SPIRIT 2013 and CONSORT 2010. Three themes, trial authors' financial conflicts of interest, data sharing, and patient and public involvement, were highlighted in the included comments. Additional themes such as remote clinical trials [37], patient-centric trials [38], basket trials, umbrella trials, and platform trials [39,40] may also be worth considering, although such issues may be better addressed in extensions than in the main reporting guidelines.

The threshold for publicly commenting on problems with SPIRIT 2013 or CONSORT 2010 may be lower than for commenting on strengths. This may explain why we found a larger number of comments on challenges than comments on strengths, which contrasts the wide use of both reporting guidelines. Authors who comment may also have a particular interest in a specific topic that may not otherwise meet the threshold for inclusion in a checklist of minimum content for all randomized trials.

4.5. Implications

SPIRIT 2013 and CONSORT 2010 are among the most well-known reporting guidelines. CONSORT has been listed as a top health research milestone in the 20th century [41]. Both SPIRIT 2013 and CONSORT 2010 are endorsed by hundreds of journals [9,10] and several prominent organizations, such as the International Committee of Medical Journal Editors [42]. We suggest that our findings provide context to users of both guidelines (e.g., trial authors, peer reviewers, editors, and readers of trials).

Furthermore, developing and revising health research reporting guidelines is an extensive process involving a series of steps including, among others, to seek feedback and criticism from various stakeholders [43]. Therefore, we suggest that the issues raised are considered for the planned updates of SPIRIT 2013 and CONSORT 2010.

5. Conclusion

We identified 114 comments on SPIRIT 2013 and CONSORT 2010, covering all aspects of the reporting guidelines but often related to the methods or results sections. Modifications were suggested to the participant flow section of

Table 3. Suggestions for new items in SPIRIT 2013 or CONSORT 2010 (46 comments in 42 documents)

SPIRIT or CONSORT section and topic	Document ID	Comment primarily intended for	Key point
Other information, comments related to funding	Leichsenring 2017	CONSORT	Include content on trialists allegiance (e.g., whether the treatment or etiological model was developed or advocated by one of the authors, whether the therapists were trained or supervised by one of the authors, whether the therapists orientation matches with trial conditions, and whether the treatments were structurally comparable in relation to duration or dose)
	duVaura 2014	CONSORT	Include content on author's financial conflicts of interest
Other information, comment related to roles and responsibilities	Conroy 2015	CONSORT	Include content on trial steering committees
Introduction, comment related to background and objectives	Gambrill 2011	CONSORT	Include content on problem framing (e.g., medicalization of common concerns)
Methods: Participants, interventions, and outcomes, comment related to participants	Ntala 2013	CONSORT	Include content regarding the methods of recruitment
Methods: Participants, interventions, and outcomes, comments related to interventions	Armijo-Olivo 2020	CONSORT	Include content on defining compliance with treatment, the methods of tracking this, and the monitoring and reporting of percentage of compliance and handling of partial compliance in the analyses
	Golomb 2010	CONSORT	Include content on the test agent (i.e., describe test agent or drug in detail, give full constituents by weight for chemical compounds, describe appearance) Include content on (placebo) control (i.e., describe (placebo) control treatment in detail, give full constituents by weight for chemical compounds, stipulate appearance and any differences from the test drug, and state what other factors might render the experience of the control distinctive from the test agent)
	Johnson 2020	CONSORT	Incorporate TIDieR items
	Levack 2020	CONSORT	Include content regarding the rationale for why an experimental intervention might be more effective than the comparison intervention
	Newton 2015	SPIRIT and CONSORT	Include content on quality of drugs and medical products used in the trial
	Rudd 2020	SPIRIT and CONSORT	Include content on intervention implementation strategies
	Shaheed 2021	CONSORT	Include content on cointerventions (covering type of intervention and frequency or duration of use)
	Verhagen 2011	CONSORT	Include content on measuring and reporting adherence to the interventions
Methods: Assignment of interventions (for controlled trials), comments related to blinding	Bian 2011	CONSORT	Include content on procedures intended to prevent, record, and deal with cases of overt unblinding, including success of blinding or risk of unblinding
	Bello 2014	SPIRIT and CONSORT	
	Bello 2017	SPIRIT and CONSORT	
	Colagiuri 2010	CONSORT	
	Colagiuri 2019	CONSORT	
Webster 2021	CONSORT		
Methods: Data collection, management, and analysis, comments related to statistical methods	Armijo-Olivo 2020	CONSORT	Include content on reporting type, purpose, conduct, and consistency of results when different analyses (intention to treat, per protocol, as treated) are conducted
	Cro 2020 ^a	SPIRIT and CONSORT	Include content on when statisticians become unblinded to the results or data
	Kahan 2021	SPIRIT and CONSORT	Include content on estimands (i.e., what treatment effect is being estimated for the primary outcome)
	Stevly 2015	CONSORT	Include content on bias correction for the early withdrawal of treatment

(Continued)

Table 3. Continued

SPRIT or CONSORT section and topic	Document ID	Comment primarily intended for	Key point
	Yelland 2018	SPIRIT and CONSORT	Include content on how recruitment, randomization, and treatment errors are handled
Methods: Monitoring, comment related to data monitoring	Korn 2011	CONSORT	Include content on reporting reasons for not prespecifying formal inefficacy monitoring or reporting reasons for not following prespecified monitoring guidelines
Ethics and dissemination, comments related to research ethics approval	Owyang 2021	CONSORT	Include content on patient and public involvement
	Strech 2014	CONSORT	Include content on ethical assessment
Ethics and dissemination, comment related to consent or assent	Pretto-Lazarova 2021	CONSORT	Include content on informed consent for special population groups (e.g., children)
Ethics and dissemination, comments related to dissemination policy	Barbui 2016 Smith 2015	CONSORT CONSORT	Include content on data sharing (covering what to share, when, and how)
Results, comments related to participant flow	Armijo-Olivo 2020	CONSORT	Include content on attrition (random or nonrandom, timing, and number and reasons for participant dropout)
	Fielding 2016 Hussain 2017 Wadood 2019	CONSORT CONSORT CONSORT	Include content on reporting missing data and retention data, including how missing data are handled (covering justification of the methods used and a missing data sensitivity analysis)
	Glasgow 2018	CONSORT	Suggestions for new sections in the CONSORT flow diagram: - Include level of setting and staff with data on participation and representativeness - Include level of setting and intervention sustainability after project support ends
	Heidari 2012	CONSORT	Include content on sex differences
	Kearney 2022	CONSORT	Include content on imputed primary outcome data and reasons for imputation
Results, comments related to recruitment	Laursen 2019	SPIRIT and CONSORT	Include content on run-in periods
	Yelland 2018	SPIRIT and CONSORT	Include content on number and type of recruitment, randomization, and treatment errors that occurred during the trial
Results, comment related to baseline data	Furler 2012	CONSORT	Include content on reporting socioeconomic status characteristics of trial participants
Results, comment related to numbers analysed	Armijo-Olivo 2020	CONSORT	Include content on participant exclusions from the analysis, reasons for exclusion, and imputation methods
Results, comment related to outcomes and estimation	Schriger 2012	CONSORT	Include content on using distributions to depict each subject's continuous outcome
Results, comment related to harms	Konwar 2022	CONSORT	Include content on safety statistics
Discussion, comment related to generalisability	Buchtele 2022	CONSORT	Include content on pragmatism
Discussion, comment related to interpretation	Glujovsky 2016	CONSORT	Include content on clinical importance

^a Key point based on quote from included document combined with personal communication with authors. In addition to the comments included in the table, one comment was not related to reporting of trial protocols or reports as the authors suggested to mention guest or ghost authorship in the CONSORT 2010 statement, for example, by referring to the ICMJE guidelines (Shaw 2010).

Table 4. Comments on challenges or strengths in SPIRIT 2013 or CONSORT 2010 (31 comments in 28 documents)

SPIRIT or CONSORT section and topic	Document ID	Comment primarily intended for	Quote
Comments on challenges			
Methods: Participants, interventions, and outcomes, comments related to interventions	Baker 2010	CONSORT	“It should be noted that the CONSORT criteria (as well developed as they are) cover only a subset of issues related to intervention evaluation”
	Page 2017	SPIRIT and CONSORT	“[...] CONSORT lists “interventions” as one of 22 items to address, asking authors to provide “precise details of the intervention intended for each group and how and when they were actually administered”. [...] Although SPIRIT also requires an intervention description as one of 33 items, it does require more specific reporting guidelines, adding detail on modifications, adherence, and concomitant interventions to the description. Such general instruction about the reporting of therapeutic interventions often leaves researchers uncertain of exactly how much to report [...]”
	Torgerson 2020	CONSORT	“The statement [CONSORT] has a single item related to the trial intervention, but fulfilment of this item does not always signify inclusion of sufficient information for researchers to reproduce the interventions in subsequent studies or for health care providers to apply these interventions in the clinical setting”
Methods: Participants, interventions, and outcomes, comment related to interventions, comment related to outcomes	Kyte 2014	SPIRIT	“[...] existing PRO [patient-reported outcome] guidance for protocol writers lacks consistency and is difficult to access, whereas PRO-specific protocol items are not fully addressed by the current SPIRIT statement”
Methods: Assignment of interventions, comments related to blinding	Cals 2011	CONSORT	“The CONSORT group has stopped advocating testing for blinding in the 2010 Statement. This removal is in our view rather unfortunate because it hinders a more thorough assessment of the success of blinding, although we agree with the remark in the 2010 main Statement that it is of limited value when assessed after the primary outcome has been reached”
	Hemilä 2010	CONSORT	“There is evident citation bias in the article by Moher et al. [the CONSORT explanation and elaboration paper]. When arguing that the lack of blinding causes bias in controlled trials, they refer to an old study which supports their preconceptions [Karlowski 1975], ignoring the evidence which indicates that the old study was erroneously analyzed. In addition, they ignore an extensive meta-analysis which analyses the effect of blinding on 60 clinical conditions [Hróbjartsson 2010]”
	Hopton 2011	CONSORT	“[...] the decision to eliminate the recommendation of CONSORT to report “how the success of blinding was evaluated” is understandable, yet the criticism of the decision as a philosophy of “let us give up because it is difficult to do or to interpret” is equally justified. The new CONSORT recommendations go some way to simplifying what should be included, but leave the assessment of blinding to be done by the readers of reports rather than those writing them”
	Kolahi 2010	CONSORT	“[...] we are concerned by the removal in the most recent iteration of CONSORT of the recommendation that authors report measures of the blindness”
	Webster 2021	CONSORT	“[...] the change in the CONSORT recommendation from asking researchers to report on success of blinding (if measured) to not asking, seems to have been based on arguments that may deserve revisiting. [...] However, the fact that CONSORT cites an article by Sackett as the reason for removing it, in which he claims that testing the success of blinding is a ‘mug’s game’ could be interpreted as a reason to avoid reporting on the success of blinding”

(Continued)

Table 4. Continued

SPRIT or CONSORT section and topic	Document ID	Comment primarily intended for	Quote
Methods: Data collection, management, and analysis, comments related to statistical methods	Cashin 2021	CONSORT	“There are no specific reporting guidelines for studies that use mediation analysis [...] CONSORT [...] do not cover the additional aspects of study design, analysis, and effects that should be reported in a mediation analysis”
	Kahan 2020	SPIRIT	“[...] however, the primary aim of these guidelines [SPIRIT] is to describe what information should be included in the protocol or Statistical Analysis Plan rather than describe exactly how the analysis should be designed. As such, these guidelines do not offer a prescriptive approach for how analysis strategies should be designed to limit p-hacking”
	Palys 2013	CONSORT	“The CONSORT description of intent to treat (ITT) also lacks precision, as authors often misrepresent what they did by referring to analyses as ITT even when some randomized patients have been excluded from these analyses [...] Nor does CONSORT call for adequate handling of missing data, so analyses based on the assumption of missing data being completely random, which is virtually unattainable in practice, can still get full credit, even if they do not also use Lachin’s conservative worst-rank approach [Lachin, Control Clin Trials 1999] for validity”
Results, comments related to participant flow	Armijo-Olivo 2020	CONSORT	“Although standard guidelines to report RCTs [randomized controlled trials] exist, such as the CONSORT statement, a lack of clear guidance on how to report and evaluate attrition and compliance related biases still remains”
	Elm 2014	CONSORT	“The general implication of this statement [the CONSORT explanation for reporting screening counts] is that by collecting screening data [in the CONSORT flow diagram] it will be possible to demonstrate the generalizability of the findings and lack of selection bias in the study subjects. This premise is, however, a relatively crude assessment because the counts themselves tell us nothing about actual specific clinical characteristics of patients with the disease of interest not included in the study”
	Palys 2013	CONSORT	“The Chalmers scale [Chalmers, Control Clin Trials 1981] calls for the log of patients screened for the trial but not randomized. This key element of trial quality, so fundamental to understanding the success of randomization, masking, and allocation concealment (3) is not an element of CONSORT”
	Patterson 2010	CONSORT	“In an attempt to quantify ‘volunteer’ bias, the widely endorsed CONSORT statement [...] encourages use of a flowchart depicting the number assessed for eligibility who declined to participate. [...] Important as this information is, it sheds little light on processes preceding assessment of eligibility, potentially masking ‘preselection’ bias”
Results, comment related to outcomes and estimation	Boers 2010	CONSORT	“In my view, summary tables and graphs are essential in conveying the principal messages of a study, so it is a pity that nothing of these results and considerations have made it into the CONSORT guidelines”
Results, comment related to harms	Tfelt-Hansen 2018	CONSORT	“[...] some of the recommendations and debated points in the CONSORT statement are irrelevant. For example, withdrawal from an RCT due to AEs [adverse events] is a highly relevant parameter for prophylactic drugs tested for treating migraines, but not for the acute-administration drugs, which are typically administered as a single dose”

(Continued)

Table 4. Continued

SPIRIT or CONSORT section and topic	Document ID	Comment primarily intended for	Quote
Ethics and dissemination, comment related to consent or assent	Kremer 2013	SPIRIT	“In your guidance [of SPIRIT] you are presenting an example schedule requiring a written informed consent as the second-earliest action. [...] I have difficulties in understanding why a written consent on participation in a randomized clinical trial should be obtained just during an initial visit. In fact, many patients (and maybe physicians) would refuse such coercion. I think that patients insisting on time for consideration are the reason for many violations in the dates when consent was in fact obtained. Auditors and inspectors will criticize “wrong” dates as violation of the protocol. But why should the protocol always require written consent at that point? So, please explain how to come to a written informed consent at the initial visit without coercion or undue influence?”
Generic comments on challenges of SPIRIT or CONSORT	Barnard 2015	CONSORT	“Furthermore, the checklist may not be sufficiently explicit. [...] The CONSORT “Explanation and Elaboration” document provides this information [explicit recommendations for reporting the intervention], but authors may be overwhelmed by reading this 28-page document mixing guidance on why each item is important and should be reported, statistics of inadequate reporting, and guidance on how to report it with examples of adequate reporting”
	Barnes 2015	CONSORT	“The Explanation and Elaboration documents are meant to help authors understand the checklist. However, these documents are very long (more than 30 pages) and they combine explanations about why the item should be reported, how the item is reported in the literature, what should be reported, and examples of adequate reporting. Consequently, the important information is buried in the manuscript. The use of a template shell with a clear and explicit reminder of what should be reported when authors are writing their manuscript could be useful to increase adherence to the guidelines”
	Blanco 2018	CONSORT	“[...] it is possible that authors are not attentive to the requirements of CONSORT or, despite their efforts to be compliant with the requirements, they are struggling to interpret certain items or the level of detail that is required”
	Dijkers 2015	CONSORT	“The list of items in CONSORT [...] is insufficient to guide complete reporting, especially for nondrug research”
	Du 2021	CONSORT	“It also helps to make the current CONSORT statement more user friendly”
	Ghosn 2019	CONSORT	“Updates of the main CONSORT are not planned with a concomitant update of existing extensions. The delay in updating extensions can be long. Consequently, an extension not based on the updated CONSORT checklist can be confusing and difficult to use because of inconsistencies in the numbering, content, and wording of items”
	Jones 2017	CONSORT	“The limitations of CONSORT must also be considered: for example, two studies may score similarly in CONSORT even if one shows markedly better outcomes than the other, as CONSORT does not evaluate the magnitude of reported outcomes. Given these inconsistencies, does the CONSORT statement have any clinical relevance?”
	Palys 2013	CONSORT	“[...] CONSORT is not sufficient for a valid trial or for good reporting. In fact, when used as a checklist for trial quality, CONSORT is essentially a subset of the more complete Chalmers scale [Chalmers, Control Clin Trials 1981]”
	Rademaker 2020	CONSORT	“It is debated that CONSORT does not include all items to properly assess trial quality, such as the lack of a randomization log, the lack of precision in the intention to treat (ITT) description, and the lack of adequate handling of missing data”

(Continued)

Table 4. Continued

SPRIT or CONSORT section and topic	Document ID	Comment primarily intended for	Quote
Comments on strengths			
Title and abstract, comment related to abstract	Dex 2010	CONSORT	“I am particularly gladdened by the addition of item 1B [in CONSORT] requiring a structured summary in line with the CONSORT abstracts recommendation”
Methods: Participants, interventions, and outcomes, comment related to sample size	Ruan 2022	CONSORT	“Scientific and reasonable estimation of sample size recommended by CONSORT can avoid false negative results owing to minimized sample size, and waste of resources induced by excessive sample size”
Other information, comment related to registration	Dex 2010	CONSORT	“However, the most important additions to the new 2010 CONSORT statement are the requirement for prospective trial registration and the making available to the editorial panel of the trial protocol. [...] Items 23 and 24 [in CONSORT, related to registration and protocol] can only improve the quality of not only trial conduct but also trial reporting”

CONSORT 2010 and new content was suggested to the sections on intervention, blinding, participant flow, and statistical methods. The issues raised may provide context to authors, peer reviewers, editors, and readers of trials using SPIRIT 2013 and CONSORT 2010 and inform the planned updates of the guidelines.

Acknowledgments

We thank Benjamin Speich, Chenchen Xu, Ariel Barrientos, and Evan Tang for assisting in assessing search records on a related project aimed at identifying empirical literature on SPIRIT 2013 and CONSORT 2010. A few of the studies identified through this project were assessed for inclusion in this scoping review.

Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jclinepi.2023.01.003>.

References

- [1] Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med* 2013;158:200–7.
- [2] Jones G, Abbasi K. Trial protocols at the BMJ. *BMJ* 2004;329:1360.
- [3] Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010;340:c332.
- [4] Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. *Lancet* 2005;365:1159–62.
- [5] Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. *JAMA* 2004;291:2457–65.
- [6] Hrobjartsson A, Pildal J, Chan AW, Haahr MT, Altman DG, Gotzsche PC. Reporting on blinding in trial protocols and corresponding publications was often inadequate but rarely contradictory. *J Clin Epidemiol* 2009;62:967–73.
- [7] Chan AW, Hrobjartsson A, Jorgensen KJ, Gotzsche PC, Altman DG. Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. *BMJ* 2008;337:a2299.
- [8] Pildal J, Chan AW, Hrobjartsson A, Forfang E, Altman DG, Gotzsche PC. Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. *BMJ* 2005;330:1049.
- [9] CONSORT Statement. Endorsers - journals and organizations. Available at <http://www.consort-statement.org/about-consort/endorsers1>. Accessed February 7, 2023.
- [10] SPIRIT Statement. Endorsement. Available at <https://www.spirit-statement.org/about-spirit-spirit-endorsement/>. Accessed February 7, 2023.
- [11] Hopewell S, Boutron I, Chan AW, Collins GS, de Beyer JA, Hróbjartsson A, et al. An update to SPIRIT and CONSORT reporting guidelines to enhance transparency in randomized trials. *Nat Med* 2022;28:1740–3.
- [12] Laursen DRT, Paludan-Müller AS, Hróbjartsson A. Randomized clinical trials with run-in periods: frequency, characteristics and reporting. *Clin Epidemiol* 2019;11:169–84.
- [13] duVaure CB, Boutron I, Perrodeau E, Ravaud P. Reporting funding source or conflict of interest in abstracts of randomized controlled trials, no evidence of a large impact on general practitioners' confidence in conclusions, a three-arm randomized controlled trial. *BMC Med* 2014;12:69.
- [14] Nejtgaard CH, Boutron I, Chan A-W, Hopewell S, Moher D, Schulz KF, et al. The evolving context of reporting randomised trials. A scoping review of comments on SPIRIT 2013 and CONSORT 2010. Available from OSF. 2022. <https://doi.org/10.17605/OSF.IO/YB98V>.
- [15] Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Ann Intern Med* 2018;169:467–73.
- [16] Meghelli L, Narducci F, Mariette C, Piessen G, Vanseymortier M, Leblanc E, et al. Reporting adverse events in cancer surgery randomized trials: a systematic review of published trials in oesophago-gastric and gynecological cancer patients. *Crit Rev Oncol Hematol* 2016;104:108–14.
- [17] Chen W, Yu J, Zhang L, Su G, Wang W, Kwong J, et al. Quality of reporting in randomized controlled trials of therapeutic cardiovascular medical devices. *Surgery* 2019;165:965–9.
- [18] Jørgensen L, Paludan-Müller AS, Laursen DRT, Savović J, Boutron I, Sterne JAC, et al. Evaluation of the Cochrane tool for assessing risk

- of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews. *Syst Rev* 2016;5:80.
- [19] McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. *J Clin Epidemiol* 2016;75:40–6.
- [20] Equator Network. Enhancing the QUALity and transparency of health research. Available at <https://www.equator-network.org/category/blog/>. Accessed February 7, 2023.
- [21] BMC. Blog Network. Available at <https://blogs.biomedcentral.com/>. Accessed February 7, 2023.
- [22] BMJ. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials - all rapid responses. Available at <https://www.bmj.com/content/340/bmj.c332/rapid-responses>. Accessed February 7, 2023.
- [23] Community C. Cochrane colloquium abstracts. Available at <https://abstracts.cochrane.org/>. Accessed February 7, 2023.
- [24] Sweetman EA, Doig GS. Failure to report protocol violations in clinical trials: a threat to internal validity? *Trials* 2011;12:214.
- [25] Zhang S, Liang F, Li W, Hu X. Subgroup analyses in reporting of phase III clinical trials in solid tumors. *J Clin Oncol* 2015;33:1697–702.
- [26] Schulz KF, Altman DG, Moher D, Fergusson D. CONSORT 2010 changes and testing blindness in RCTs. *Lancet* 2010;375:1144–6.
- [27] Siddiq H, Pentapati KC, Acharya S. Adherence of randomized controlled trials to consolidated standards of reporting trials 2010 guidelines: a survey of randomized controlled trials published in 2011–2016 in 3 periodontology journals. *J Evid Based Dent Pract* 2019;19:260–72.
- [28] Barbui C. Sharing all types of clinical data and harmonizing journal standards. *BMC Med* 2016;14:63.
- [29] Smith CT, Hopkins C, Sydes MR, Woolfall K, Clarke M, Murray G, et al. How should individual participant data (IPD) from publicly funded clinical trials be shared? *BMC Med* 2015;13:298.
- [30] Owyang D, Bakhsh A, Brewer D, Boughton OR, Cobb JP. Patient and public involvement within orthopaedic research: a systematic review. *J Bone Joint Surg Am* 2021;103:e51.
- [31] Vassar M, Jellison S, Wendelbo H, Wayant C, Gray H, Bibens M. Using the CONSORT statement to evaluate the completeness of reporting of addiction randomised trials: a cross-sectional review. *BMJ Open* 2019;9:e032024.
- [32] Yin Y, Shi F, Zhang Y, Zhang X, Ye J, Zhang J. Evaluation of reporting quality of randomized controlled trials in patients with COVID-19 using the CONSORT statement. *PLoS One* 2021;16:e0257093.
- [33] Mozetic V, Leonel L, Leite Pacheco R, de Oliveira Cruz Latorraca C, Guimarães T, Logullo P, et al. Reporting quality and adherence of randomized controlled trials about statins and/or fibrates for diabetic retinopathy to the CONSORT checklist. *Trials* 2019;20:729.
- [34] Turner L, Shamseer L, Altman DG, Weeks L, Peters J, Kober T, et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. *Cochrane Database Syst Rev* 2012;11:MR000030.
- [35] Hopewell S, Ravau P, Baron G, Boutron I. Effect of editors' implementation of CONSORT guidelines on the reporting of abstracts in high impact medical journals: interrupted time series analysis. *BMJ* 2012;344:e4178.
- [36] Chauvin A, Ravau P, Moher D, Schriger D, Hopewell S, Shanahan D, et al. Accuracy in detecting inadequate research reporting by early career peer reviewers using an online CONSORT-based peer-review tool (COBPeer) versus the usual peer-review process: a cross-sectional diagnostic study. *BMC Med* 2019;17:205.
- [37] Alemayehu D, Hemmings R, Natarajan K, Roychoudhury S. Perspectives on virtual (remote) clinical trials as the “new normal” to accelerate drug development. *Clin Pharmacol Ther* 2022;111:373–81.
- [38] Sharma NS. Patient centric approach for clinical trials: current trend and new opportunities. *Perspect Clin Res* 2015;6:134–8.
- [39] Park JJH, Siden E, Zoratti MJ, Dron L, Harari O, Singer J, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. *Trials* 2019;20:572.
- [40] Strzebonska K, Waligora M. Umbrella and basket trials in oncology: ethical challenges. *BMC Med Ethics* 2019;20:58.
- [41] Gabriel SE, Normand SL. Getting the methods right - the foundation of patient-centered outcomes research. *N Engl J Med* 2012;367:787–90.
- [42] International Committee of Medical Journal Editors. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. Available at <https://www.icmje.org/icmje-recommendations.pdf>. Accessed February 7, 2023.
- [43] Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. *PLoS Med* 2010;7:e1000217.